{{Drugbox
| Verifiedfields = 
| Watchedfields = 
| verifiedrevid = 
| IUPAC_name = 2-Amino-''N''-[(2''R'')-1-[(3''R'')-3-benzyl-3-[dimethylamino(methyl)carbamoyl]piperidin-1-yl]-3-(1''H''-indol-3-yl)-1-oxopropan-2-yl]-2-methylpropanamide
| image = Anamorelin.svg
| width = 200

<!--Clinical data-->
| tradename = 
| pregnancy_AU = <!-- A / B1 / B2 / B3 / C / D / X -->
| pregnancy_US = <!-- A / B            / C / D / X -->
| pregnancy_category = 
| legal_AU = <!-- Unscheduled / S2 / S3 / S4 / S5 / S6 / S7 / S8 / S9 -->
| legal_CA = 
| legal_UK = 
| legal_US = 
| legal_status = 
| routes_of_administration = Oral

<!--Pharmacokinetic data-->
| bioavailability = 
| protein_bound = 
| metabolism = 
| elimination_half-life = 6–7 hours<ref name="LeeseTrang2015">{{cite journal|last1=Leese|first1=Philip T.|last2=Trang|first2=John M.|last3=Blum|first3=Robert A.|last4=de Groot|first4=Eleanor|title=An open-label clinical trial of the effects of age and gender on the pharmacodynamics, pharmacokinetics and safety of the ghrelin receptor agonist anamorelin|journal=Clinical Pharmacology in Drug Development|volume=4|issue=2|year=2015|pages=112–120|issn=2160-763X|doi=10.1002/cpdd.175}}</ref>
| excretion =

<!--Identifiers-->
| CAS_number_Ref = 
| CAS_number = 249921-19-5
| CAS_supplemental = 
| ATC_prefix = None
| ATC_suffix = 
| PubChem = 9828911
| DrugBank_Ref = 
| DrugBank = 
| ChemSpiderID_Ref = 
| ChemSpiderID = 8004650

<!--Chemical data-->
| C=31 | H=42 | N=6 | O=3
| molecular_weight = 546.70358 g/mol
| smiles = CC(C)(C(=O)NC(CC1=CNC2=CC=CC=C21)C(=O)N3CCCC(C3)(CC4=CC=CC=C4)C(=O)N(C)N(C)C)N
| StdInChI = 1S/C31H42N6O3/c1-30(2,32)28(39)34-26(18-23-20-33-25-15-10-9-14-24(23)25)27(38)37-17-11-16-31(21-37,29(40)36(5)35(3)4)19-22-12-7-6-8-13-22/h6-10,12-15,20,26,33H,11,16-19,21,32H2,1-5H3,(H,34,39)/t26-,31-/m1/s1
| StdInChIKey = VQPFSIRUEPQQPP-MXBOTTGLSA-N
| synonyms = 
}}

'''Anamorelin''' ([[International Nonproprietary Name|INN]]) (developmental code names '''ONO-7643''', '''RC-1291''', '''ST-1291'''), also known as '''anamorelin hydrochloride''' ([[United States Adopted Name|USAN]], [[Japanese Accepted Name|JAN]]), is a [[non-peptide]], [[Oral administration|orally-active]], [[central nervous system|centrally-penetrant]], selective [[agonist]] of the [[growth hormone secretagogue receptor|ghrelin/growth hormone secretagogue receptor]] (GHSR) with [[orexigenic|appetite-enhancing]] and [[anabolic]] effects which is under development by [[Helsinn Healthcare SA]] for the treatment of [[cancer cachexia|cancer cachexia and anorexia]].<ref name="CurrowAbernethy2014">{{cite journal|last1=Currow|first1=David C|last2=Abernethy|first2=Amy P|title=Anamorelin hydrochloride in the treatment of cancer anorexia-cachexia syndrome|journal=Future Oncology|volume=10|issue=5|year=2014|pages=789–802|issn=1479-6694|doi=10.2217/fon.14.14}}</ref><ref name="GarciaPolvino2009">{{cite journal|last1=Garcia|first1=José M.|last2=Polvino|first2=William J.|title=Pharmacodynamic hormonal effects of anamorelin, a novel oral ghrelin mimetic and growth hormone secretagogue in healthy volunteers|journal=Growth Hormone & IGF Research|volume=19|issue=3|year=2009|pages=267–273|issn=1096-6374|doi=10.1016/j.ghir.2008.12.003}}</ref><ref name="GarciaBoccia2015">{{cite journal|last1=Garcia|first1=José M|last2=Boccia|first2=Ralph V|last3=Graham|first3=Charles D|last4=Yan|first4=Ying|last5=Duus|first5=Elizabeth Manning|last6=Allen|first6=Suzan|last7=Friend|first7=John|title=Anamorelin for patients with cancer cachexia: an integrated analysis of two phase 2, randomised, placebo-controlled, double-blind trials|journal=The Lancet Oncology|volume=16|issue=1|year=2015|pages=108–116|issn=1470-2045|doi=10.1016/S1470-2045(14)71154-4}}</ref>

Anamorelin significantly increases plasma levels of [[growth hormone]] (GH), [[insulin-like growth factor 1]] (IGF-1), and [[insulin-like growth factor-binding protein 3]] (IGFBP-3) in humans, without affecting plasma levels of [[prolactin]], [[cortisol]], [[insulin]], [[glucose]], [[adrenocorticotropic hormone]] (ACTH), [[luteinizing hormone]] (LH), [[follicle-stimulating hormone]] (FSH), or [[thyroid-stimulating hormone]] (TSH).<ref name="GarciaPolvino2009" /><ref name="GarciaFriend2012">{{cite journal|last1=Garcia|first1=José M.|last2=Friend|first2=John|last3=Allen|first3=Suzan|title=Therapeutic potential of anamorelin, a novel, oral ghrelin mimetic, in patients with cancer-related cachexia: a multicenter, randomized, double-blind, crossover, pilot study|journal=Supportive Care in Cancer|volume=21|issue=1|year=2012|pages=129–137|issn=0941-4355|doi=10.1007/s00520-012-1500-1}}</ref> In addition, anamorelin significantly increases [[appetite]], overall [[body weight]], [[lean body mass]], and [[physical strength|muscle strength]],<ref name="GarciaBoccia2015" /><ref name="GarciaFriend2012" /> with increases in body weight correlating directly with increases in plasma IGF-1 levels.<ref name="GarciaPolvino2009" />

As of February 2016, anamorelin has completed [[Phases of clinical research#Phase III|phase III]] [[clinical trial]]s for the treatment of cancer cachexia and anorexia associated with [[non-small-cell lung carcinoma]].<ref name="ZhangGarcia2015">{{cite journal|last1=Zhang|first1=Hongjie|last2=Garcia|first2=Jose M|title=Anamorelin hydrochloride for the treatment of cancer-anorexia-cachexia in NSCLC|journal=Expert Opinion on Pharmacotherapy|volume=16|issue=8|year=2015|pages=1245–1253|issn=1465-6566|doi=10.1517/14656566.2015.1041500}}</ref><ref name="TemelAbernethy2016">{{cite journal|last1=Temel|first1=Jennifer S|last2=Abernethy|first2=Amy P|last3=Currow|first3=David C|last4=Friend|first4=John|last5=Duus|first5=Elizabeth M|last6=Yan|first6=Ying|last7=Fearon|first7=Kenneth C|title=Anamorelin in patients with non-small-cell lung cancer and cachexia (ROMANA 1 and ROMANA 2): results from two randomised, double-blind, phase 3 trials|journal=The Lancet Oncology|volume=17|issue=4|year=2016|pages=519–531|issn=1470-2045|doi=10.1016/S1470-2045(15)00558-6}}</ref>

On 18 May 2017, the [[European Medicines Agency]] recommended the refusal of the marketing authorisation for the medicinal product, intended for the treatment of anorexia, cachexia or unintended weight loss in patients with non-small cell lung cancer.
Helsinn requested a re-examination of the initial opinion. After considering the grounds for this request, the European Medicines Agency re-examined the opinion, and confirmed the refusal of the marketing authorisation on 14 September 2017.<ref>http://www.ema.europa.eu/ema/index.jsp?curl=pages/medicines/human/medicines/003847/smops/Negative/human_smop_001130.jsp&mid=WC0b01ac058001d127</ref>
The European Medicines Agency concluded that the studies show a marginal effect of anamorelin on lean body mass and no proven effect on hand grip strength or patients’ quality of life. In addition, following an inspection at clinical study sites, the agency considered that the safety data on the medicine had not been recorded adequately. Therefore the agency was of the opinion that the benefits of anamorelin did not outweigh its risks.<ref>www.ema.europa.eu/docs/en_GB/document_library/Summary_of_opinion_-_Initial_authorisation/human/003847/WC500228047.pdf</ref>

==See also==
* [[Capromorelin]]
* [[Examorelin|Examorelin (hexarelin)]]
* [[GHRP-6|GHRP-6 (SKF-110679)]]
* [[Ibutamoren|Ibutamoren (MK-677)]]
* [[Ipamorelin]]
* [[Macimorelin]]
* [[Pralmorelin|Pralmorelin (GHRP-2)]]
* [[Relamorelin]]
* [[SM-130,686]]
* [[Tabimorelin]]

==References==
{{Reflist|2}}

==External links==
* [http://adisinsight.springer.com/drugs/800021124 Anamorelin - AdisInsight]

{{Orexigenics}}
{{GH/IGF-1 axis signaling modulators}}

[[Category:Amines]]
[[Category:Appetite stimulants]]
[[Category:Carbamates]]
[[Category:Ghrelin receptor agonists]]
[[Category:Growth hormone secretagogues]]
[[Category:Hormonal agents]]
[[Category:Indoles]]
[[Category:Piperidines]]
[[Category:World Anti-Doping Agency prohibited substances]]
[[Category:Experimental drugs]]


{{systemic-hormonal-drug-stub}}